Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3717
Name gastric adenocarcinoma
Definition A stomach carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer stomach cancer stomach carcinoma gastric adenocarcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Paclitaxel + Ramucirumab gastric adenocarcinoma not applicable detail...
ERBB2 amp Trastuzumab gastric adenocarcinoma sensitive detail...
Unknown unknown Ramucirumab gastric adenocarcinoma not applicable detail...
Unknown unknown MK2206 gastric adenocarcinoma not applicable detail...
PIK3CA mutant Fluorouracil + PI-103 gastric adenocarcinoma sensitive detail...
Unknown unknown Torkinib gastric adenocarcinoma not applicable detail...
Unknown unknown Paclitaxel + Ridaforolimus gastric adenocarcinoma not applicable detail...
Unknown unknown Celecoxib + Sirolimus gastric adenocarcinoma not applicable detail...
ERBB2 over exp VS-5584 gastric adenocarcinoma sensitive detail...
ERBB2 amp Lapatinib gastric adenocarcinoma no benefit detail...
Unknown unknown Regorafenib gastric adenocarcinoma not applicable detail...
Unknown unknown Paclitaxel + Tegafur-gimeracil-oteracil Potassium gastric adenocarcinoma not applicable detail...
ERBB2 positive Ado-trastuzumab emtansine gastric adenocarcinoma no benefit detail...
Unknown unknown Panitumumab gastric adenocarcinoma no benefit detail...
Unknown unknown Rivoceranib gastric adenocarcinoma not applicable detail...
Unknown unknown Napabucasin + Paclitaxel gastric adenocarcinoma not applicable detail...
FGFR2 amp AZD4547 gastric adenocarcinoma no benefit detail...
ERBB2 over exp Trastuzumab gastric adenocarcinoma sensitive detail...
ERBB2 over exp Capecitabine + Lapatinib + Oxaliplatin gastric adenocarcinoma predicted - sensitive detail...
ERBB2 amp Capecitabine + Lapatinib + Oxaliplatin gastric adenocarcinoma predicted - sensitive detail...
Unknown unknown Nivolumab + Ramucirumab gastric adenocarcinoma not applicable detail...
Unknown unknown Oxaliplatin + Ramucirumab + Tegafur-gimeracil-oteracil Potassium gastric adenocarcinoma no benefit detail...
ERBB2 positive Afatinib gastric adenocarcinoma predicted - sensitive detail...
ERBB2 positive Afatinib + Trastuzumab gastric adenocarcinoma predicted - sensitive detail...
Unknown unknown Minnelide gastric adenocarcinoma not applicable detail...
Unknown unknown Irinotecan + Minnelide gastric adenocarcinoma not applicable detail...
Unknown unknown Triptolide gastric adenocarcinoma not applicable detail...
ERBB2 over exp Trastuzumab-anns gastric adenocarcinoma sensitive detail...
Unknown unknown Nintedanib gastric adenocarcinoma not applicable detail...
Unknown unknown Capecitabine + Oxaliplatin + Toripalimab gastric adenocarcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00780494 Phase II Bevacizumab + Capecitabine + Carboplatin Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma Completed
NCT01191697 Phase II Bevacizumab + Trastuzumab Capecitabine + Oxaliplatin CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer Active, not recruiting
NCT01450696 Phase III Capecitabine + Cisplatin + Trastuzumab HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer Terminated
NCT01526473 Phase I AVX901 A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Completed
NCT01662869 Phase III Onartuzumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric) Completed
NCT01747551 Phase II Aflibercept Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Completed
NCT01774786 Phase III Pertuzumab Capecitabine + Cisplatin + Fluorouracil + Trastuzumab A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed
NCT01774851 Phase II MM-111 + Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Terminated
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed
NCT01896531 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ipatasertib A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Active, not recruiting
NCT01913639 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer Completed
NCT02016534 Phase II AMG 337 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Terminated
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
NCT02065765 Phase II Ramucirumab International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer No longer available
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed
NCT02178956 Phase III Napabucasin Paclitaxel A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02213289 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Docetaxel + Fluorouracil Trastuzumab Fluorouracil + Irinotecan + Leucovorin Rilotumumab PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Active, not recruiting
NCT02234596 Phase II Nintedanib Nintedanib in Patients With Advanced Esophagogastric Cancer Completed
NCT02241720 Phase II Regorafenib Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers Terminated
NCT02264678 Phase Ib/II AZD6738 AZD6738 + Carboplatin AZD6738 + Durvalumab AZD6738 + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting
NCT02283359 Phase I Irinotecan + Selinexor Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus Terminated
NCT02317991 Phase II Nab-paclitaxel + Ramucirumab Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Active, not recruiting
NCT02335411 Phase II Cisplatin + Fluorouracil + Pembrolizumab Pembrolizumab A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Active, not recruiting
NCT02340975 Phase Ib/II Durvalumab Tremelimumab A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Completed
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Active, not recruiting
NCT02494583 Phase III Capecitabine Cisplatin + Fluorouracil Pembrolizumab Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Active, not recruiting
NCT02500043 Phase III trifluridine/tipiracil hydrochloride Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02514551 Phase II Paclitaxel Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Completed
NCT02545504 Phase III Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Andecaliximab GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed
NCT02551055 Phase I Docetaxel Paclitaxel Alisertib Mivavotinib MLN1117 MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated
NCT02563548 Phase I PEGPH20 + Pembrolizumab Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab Completed
NCT02564900 Phase I Trastuzumab deruxtecan Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Active, not recruiting
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Active, not recruiting
NCT02574663 Phase I Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Completed
NCT02597036 Phase I LY3127804 Ramucirumab A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Active, not recruiting
NCT02599324 Phase Ib/II Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting
NCT02625610 Phase III Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Avelumab Capecitabine + Oxaliplatin Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100) Active, not recruiting
NCT02625623 Phase III Avelumab Paclitaxel Irinotecan Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated
NCT02675946 Phase I CGX1321 Study of CGX1321 in Subjects With Advanced Solid Tumors Recruiting
NCT02689284 Phase Ib/II Margetuximab + Pembrolizumab Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Active, not recruiting
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Active, not recruiting
NCT02773524 Phase III Regorafenib A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) Recruiting
NCT02864381 Phase II Nivolumab Andecaliximab + Nivolumab GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Completed
NCT02908451 Phase I AbGn-107 A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer Active, not recruiting
NCT02918162 Phase II Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab Perioperative Chemo and Pembrolizumab in Gastric Cancer Recruiting
NCT02943603 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach Withdrawn
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Recruiting
NCT03042611 Phase III Rivoceranib Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer Active, not recruiting
NCT03064490 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) Recruiting
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Active, not recruiting
NCT03122548 Phase II CRS-207 + Pembrolizumab Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers Terminated
NCT03141034 Phase II Irinotecan + Ramucirumab Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Recruiting
NCT03193918 Phase I Crenolanib + Paclitaxel + Ramucirumab Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma Completed
NCT03196232 Phase II Epacadostat + Pembrolizumab Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Completed
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Recruiting
NCT03221426 Phase III Capecitabine + Cisplatin Capecitabine + Cisplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Recruiting
NCT03257163 Phase II Capecitabine + Pembrolizumab Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Recruiting
NCT03281369 Phase Ib/II Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + MTIG7192A Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + MTIG7192A A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) Recruiting
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03321630 Phase II Lenvatinib + Pembrolizumab A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies Recruiting
NCT03365791 Phase II LAG525 Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Active, not recruiting
NCT03368963 Phase Ib/II MM-398 + trifluridine/tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Active, not recruiting
NCT03407976 Phase Ib/II Pembrolizumab + Rivoceranib Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Terminated
NCT03427814 Phase III Pamiparib Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer Active, not recruiting
NCT03488667 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma Recruiting
NCT03504397 Phase III Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight) Recruiting
NCT03505320 Phase II Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Pembrolizumab + Zolbetuximab A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (ILUSTRO) Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03539822 Phase I Cabozantinib + Durvalumab Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) Recruiting
NCT03588039 Phase I Oraxol + Pembrolizumab Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT03597581 Phase I RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 A Study of RGX-202-01 With or Without FOLFIRI in Patients With Advanced Gastrointestinal Malignancies Recruiting
NCT03615326 Phase III Oxaliplatin + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Recruiting
NCT03653507 Phase III Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Zolbetuximab A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW) Recruiting
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Recruiting
NCT03675737 Phase III Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Recruiting
NCT03686488 Phase II Ramucirumab + trifluridine/tipiracil hydrochloride TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Recruiting
NCT03694522 Phase II Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT) Active, not recruiting
NCT03697304 Phase II BI 754091 BI 754111 Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. Suspended
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Recruiting
NCT03739801 Phase Ib/II MM-398 + Ramucirumab MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Withdrawn
NCT03752398 Phase I XmAb23104 A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Recruiting
NCT03776487 Phase Ib/II Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer Recruiting
NCT03777657 Phase III Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Recruiting
NCT03783936 Phase II Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Recruiting
NCT03809624 Phase I INBRX-105 Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB) Recruiting
NCT03840967 Phase II Niraparib A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Recruiting
NCT03918499 Phase Ib/II Cyclophosphamide + IRX-2 + Pembrolizumab IRX-2, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Suspended
NCT03954704 Phase I Fluorouracil + GS-1423 + Leucovorin + Oxaliplatin GS-1423 Study of GS-1423 in Participants With Advanced Solid Tumors Recruiting
NCT03995017 Phase Ib/II Ramucirumab + Rucaparib Nivolumab + Ramucirumab + Rucaparib Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME) Recruiting
NCT03997448 Phase II Abemaciclib + Pembrolizumab Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 Active, not recruiting
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting
NCT04021108 Phase II Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Recruiting
NCT04029922 Phase I MT-5111 Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) Recruiting
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Recruiting
NCT04041310 Phase I GAd-209-FSP + MVA-209-FSP Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Recruiting
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting
NCT04074343 Phase I Irinotecan + trifluridine/tipiracil hydrochloride TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma Recruiting
NCT04089904 Phase II Pembrolizumab Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma Recruiting
NCT04099641 Phase II Bavituximab + Pembrolizumab An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Recruiting
NCT04111172 Phase II Ad5.F35-hGCC-PADRE Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies Not yet recruiting
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Recruiting
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Not yet recruiting
NCT04117958 Phase I AMG 199 Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer Recruiting
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting
NCT04164979 Phase II Cabozantinib + Pembrolizumab Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma Recruiting
NCT04171141 Phase I PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. Recruiting
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting
NCT04379596 Phase II Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab Fluorouracil + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Durvalumab + Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab deruxtecan Capecitabine + Oxaliplatin + Trastuzumab deruxtecan Durvalumab + Fluorouracil + Trastuzumab deruxtecan Capecitabine + Durvalumab + Trastuzumab deruxtecan Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (DG-03) Recruiting
NCT04450732 Phase I GQ1001 Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Not yet recruiting